The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Open accessAbstract
Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Due to the precision afforded by complementary binding of an ASO to its target transcript of interest, ASOs have emerged as an invaluable tool in specifically altering levels and/or processing of a variety of proteins involved in neurodegenerative diseases, most of which have been the disease-causing protein itself (38, 51–54).”
From Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration (2023) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Self-citationReaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-43 · Cited by 1,285
Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998) · Science · doi:10.1126/science.281.5384.1851 · Cited by 1,250
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Kaspar, B. K., Lladó, J., Sherkat, N., Rothstein, J. D., & Gage, F. H. (2003) · Science · doi:10.1126/science.1086137 · Cited by 872
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationWild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS
Bosco, D. A., Morfini, G. A., Karabacak, M., Song, Y., Gros‐Louis, F., Pasinelli, P., Goolsby, H., Fontaine, B. A., Lemay, N., McKenna-Yasek, D. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2660 · Cited by 685
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationLagier‐Tourenne, C., Baughn, M. W., Rigo, F., Sun, S., Liu, P., Li, H., Jiang, J., Watt, A. T., Chun, S. J., Katz, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318835110 · Cited by 585
Self-citation
Cited by
Sorted by citations
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204705 · Cited by 966
Self-citationPhase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565
Self-citationMead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
ALS Genetics: Gains, Losses, and Implications for Future Therapies
Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.022 · Cited by 370
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353
Self-citationKnockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model
Guttenplan, K. A., Weigel, M. K., Adler, D. I., Couthouis, J., Liddelow, S. A., Gitler, A. D., & Barres, B. A. (2020) · Nature Communications · doi:10.1038/s41467-020-17514-9 · Cited by 278
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Mueller, C., Berry, J. D., McKenna-Yasek, D. M., Gernoux, G., Owegi, M. A., Pothier, L. M., Douthwright, C. L., Gelevski, D., Luppino, S. D., Blackwood, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005056 · Cited by 264
Self-citationRoot, J. T., Merino, P., Nuckols, A., Johnson, M. A., & Kukar, T. L. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105360 · Cited by 243
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
Gagliardi, M. E., & Ashizawa, A. T. (2021) · Biomedicines · doi:10.3390/biomedicines9040433 · Cited by 217
Scoles, D. R., Minikel, E. V., & Pulst, S. M. (2019) · Neurology Genetics · doi:10.1212/nxg.0000000000000323 · Cited by 201
Evaluating drug targets through human loss-of-function genetic variation
Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2267-z · Cited by 188
Benatar, M. G., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., Otto, M., Farahany, N. A., Harrington, E. A., Chen, W., Mitchell, A. A., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01237-4 · Cited by 182
Self-citationSuppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide
Tran, H., Moazami, M. P., Yang, H., McKenna-Yasek, D., Douthwright, C. L., Pinto, C., Metterville, J., Shin, M., Sanil, N., Dooley, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01557-6 · Cited by 174
Liu, M., Wang, Y., Zhang, Y.-B., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02112-8 · Cited by 180
Pereira, J. D., DuBreuil, D. M., Devlin, A., Held, A., Sapir, Y., Berezovski, E., Hawrot, J., Dorfman, K., Chander, V., & Wainger, B. J. (2021) · Nature Communications · doi:10.1038/s41467-021-24776-4 · Cited by 159
Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
Ramasamy, T., Ruttala, H. B., Munusamy, S., Chakraborty, N., & Kim, J. O. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.050 · Cited by 155
Antisense oligonucleotides extend survival of prion-infected mice
Raymond, G. J., Zhao, H. T., Race, B., Raymond, L. D., Williams, K., Swayze, E. E., Graffam, S., Le, J., Caron, T. J., Stathopoulos, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131175 · Cited by 148
Self-citationLenk, G. M., Jafar‐Nejad, P., Hill, S. F., Huffman, L. D., Smolen, C., Wagnon, J. L., Petit, H. J., Yu, W., Ziobro, J. M., Bhatia, K., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25676 · Cited by 144
Wainger, B. J., Macklin, E. A., Vucic, S., McIlduff, C. E., Paganoni, S., Maragakis, N. J., Bedlack, R., Goyal, N., Rutkove, S. B., Lange, D. J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4300 · Cited by 142
Self-citationDiagnostic and Prognostic Performance of Neurofilaments in ALS
Poesen, K., & Damme, P. V. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2018.01167 · Cited by 142
Nagata, T., Dwyer, C. A., Yoshida‐Tanaka, K., Ihara, K., Ohyagi, M., Kaburagi, H., Miyata, H., Ebihara, S., Yoshioka, K., Ishii, T., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00972-x · Cited by 140
Self-citationJafar-nejad, P., Powers, B., Soriano, A., Zhao, H., Norris, D. A., Matson, J., DeBrosse-Serra, B., Watson, J., Narayanan, P., Chun, S. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1235 · Cited by 128
Self-citationNeuromuscular Junction Dysfunction in Amyotrophic Lateral Sclerosis
Verma, S., Khurana, S., Vats, A., Sahu, B., Ganguly, N. K., Chakraborti, P., Gourie-Devi, M., & Taneja, V. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02658-6 · Cited by 126
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
Rook, M. E., & Southwell, A. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00519-9 · Cited by 118
Bravo‐Hernández, M., Tadokoro, T., Navarro, M. R., Platoshyn, O., Kobayashi, Y., Marsala, S., Miyanohara, A., Juhás, Š., Juhásová, J., Skalníková, H. K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0674-1 · Cited by 118
Longitudinal biomarkers in amyotrophic lateral sclerosis
Huang, F., Zhu, Y., Hsiao‐Nakamoto, J., Tang, X., Dugas, J. C., Moscovitch‐Lopatin, M., Glass, J. D., Brown, R. H., Ladha, S. S., Lacomis, D., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51078 · Cited by 111
Ningarhari, M., Caruso, S., Hirsch, T. Z., Bayard, Q., Franconi, A., Védié, A., Noblet, B., Blanc, J., Amaddeo, G., Ganne‐Carrié, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.052 · Cited by 118
Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging
Mazur, C., Powers, B., Zasadny, K., Sullivan, J. M., Dimant, H., Kamme, F., Hesterman, J., Matson, J., Oestergaard, M., Seaman, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129240 · Cited by 114
Self-citationAbati, E., Bresolin, N., Comi, G. P., & Corti, S. P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1738390 · Cited by 106
Antisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
Self-citationNeurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers
Zucchi, E., Bonetto, V., Sorarú, G., Martinelli, I., Parchi, P., Liguori, R., & Mandrioli, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00406-3 · Cited by 112
Meyer, T., Schumann, P., Weydt, P., Petri, S., Koc, Y., Spittel, S., Bernsen, S., Günther, R., Weishaupt, J. H., Dreger, M., et al. (2023) · Muscle & Nerve · doi:10.1002/mus.27818 · Cited by 104
Antisense Oligonucleotides for the Study and Treatment of ALS
Boros, B. D., Schoch, K. M., Kreple, C. J., & Miller, T. M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01247-2 · Cited by 111
Self-citationGene Therapy for ALS—A Perspective
Cappella, M., Ciotti, C., Cohen-Tannoudji, M., & Biferi, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184388 · Cited by 101
Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis
Xue, Y. C., Ng, C. S., Xiang, P., Liu, H., Zhang, K., Mohamud, Y., & Luo, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00078 · Cited by 94
Dindot, S. V., Christian, S., Murphy, W. J., Berent, A., Panagoulias, J., Schlafer, A., Ballard, J. L., Radeva, K., Robinson, R., Myers, L. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abf4077 · Cited by 97
Targeted gene silencing in the nervous system with CRISPR-Cas13
Powell, J. E., Lim, C. K. W., Krishnan, R. S. G., McCallister, T. X., Saporito-Magriñá, C., C., M. A. Z., McPheron, G. D., & Gaj, T. (2022) · Science Advances · doi:10.1126/sciadv.abk2485 · Cited by 96
SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis
Park, J. H., Elpers, C., Reunert, J., McCormick, M. L., Mohr, J., Biskup, S., Schwartz, O., Rust, S., Grüneberg, M., Seelhöfer, A., et al. (2019) · Brain · doi:10.1093/brain/awz182 · Cited by 88
Towards a treatment for genetic prion disease: trials and biomarkers
Vallabh, S. M., Minikel, E. V., Schreiber, S. L., & Lander, E. S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30403-x · Cited by 88
Fluid biomarkers for amyotrophic lateral sclerosis: a review
Irwin, K. E., Sheth, U., Wong, P. C., & Gendron, T. F. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00685-6 · Cited by 95
The human motor cortex microcircuit: insights for neurodegenerative disease
McColgan, P., Joubert, J., Tabrizi, S. J., & Rees, G. E. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-0315-1 · Cited by 92
Notch and the regulation of osteoclast differentiation and function
Yu, J., & CANALIS, E. M. (2020) · Bone · doi:10.1016/j.bone.2020.115474 · Cited by 83
Duan, W., Guo, M., Yi, L., Liu, Y., Li, Z., Ma, Y., Zhang, G., Liu, Y., Bu, H., Song, X., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0116-1 · Cited by 79
Noh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 94
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases
Chen, S., Heendeniya, S. N., Le, B. T., Rahimizadeh, K., Rabiee, N., Zahra, Q. U. A., & Veedu, R. N. (2024) · BioDrugs · doi:10.1007/s40259-024-00644-7 · Cited by 80
The physiological and pathophysiological roles of copper in the nervous system
Gale, J. R., & Aizenman, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16370 · Cited by 85
Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies
Yang, X., Ji, Y., Wang, W., Zhang, L., Chen, Z., Yu, M., Shen, Y., Ding, F., Gu, X., & Sun, H. (2021) · Antioxidants · doi:10.3390/antiox10071012 · Cited by 80
Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis
Ly, C. V., & Miller, T. M. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000594 · Cited by 69
Self-citationProtein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS
Tsekrekou, M., Giannakou, M., Papanikolopoulou, K., & Σκρέτας, Γ. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1383453 · Cited by 71
Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets
Niu, X., Zhang, L., Wu, Y., Zong, Z., Wang, B., Liu, J., Zhang, L., & Zhou, F. (2023) · MedComm · doi:10.1002/mco2.223 · Cited by 73
Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention
Benatar, M. G., Robertson, J., & Andersen, P. M. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00479-4 · Cited by 73
Eide, P. K., Mariussen, E., Uggerud, H. T., Pripp, A. H., Lashkarivand, A., Hassel, B., Christensen, H., Hovd, M. H., & Ringstad, G. A. (2021) · JCI Insight · doi:10.1172/jci.insight.147063 · Cited by 64
Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS
Deng, H., Zhai, H., Shi, Y., Liu, G., Lowry, J., Liu, B., Ryan, É. B., Yan, J., Yang, Y., Zhang, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01942-4 · Cited by 66
Huang, M., Liu, Y. U., Yao, X., Qin, D., & Su, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00416-x · Cited by 64
Deconvoluting the Complexity of Reactive Oxygen Species (ROS) in Neurodegenerative Diseases
Zhou, Y., Zhen, Y., Wang, G., & Liu, B. (2022) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2022.910427 · Cited by 61
Mitochondria, a Key Target in Amyotrophic Lateral Sclerosis Pathogenesis
Genin, E. C., Abou-Ali, M., & Paquis‐Flucklinger, V. (2023) · Genes · doi:10.3390/genes14111981 · Cited by 64
Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives
Ediriweera, G. R., Chen, L., Yerbury, J. J., Thurecht, K. J., & Vine, K. L. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00297 · Cited by 57
Mir-17∼92 Confers Motor Neuron Subtype Differential Resistance to ALS-Associated Degeneration
Tung, Y.-T., Peng, K.-C., Chen, Y.-C., Yen, Y.-P., Chang, M., Thams, S., & Chen, J.-A. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.016 · Cited by 53
A single-cell map of antisense oligonucleotide activity in the brain
Mortberg, M. A., Gentile, J. E., Nadaf, N. M., Vanderburg, C., Simmons, S., Dubinsky, D., Slamin, A., Maldonado, S., Petersen, C. L., Jones, N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad371 · Cited by 54
Self-citationvan Roon‐Mom, W., Ferguson, C. M., & Aartsma-Rus, A. M. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0027 · Cited by 51
The 2022 Lady Estelle Wolfson lectureship on neurofilaments
Petzold, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15682 · Cited by 52
Adams, D., Algalarrondo, V., Polydefkis, M. J., Sarswat, N., Slama, M., & Nativi-Nicolau, J. N. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01960-9 · Cited by 53
Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
Berber, B., Aydın, C., Kocabaş, F., Güney-Esken, G., Yılancıoğlu, K., Alpaslan, M. K., Çalıseki, M., Yüce, M., Demir, S., & Taştan, C. (2020) · Gene Therapy · doi:10.1038/s41434-020-00209-7 · Cited by 52
Yang, A., Kantor, B., & Chiba‐Falek, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031244 · Cited by 51
Hovd, M. H., Mariussen, E., Uggerud, H. T., Lashkarivand, A., Christensen, H., Ringstad, G. A., & Eide, P. K. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00352-w · Cited by 52
Saini, A., & Chawla, P. A. (2023) · European Journal of Neurology · doi:10.1111/ene.16140 · Cited by 49
Alternative Splicing of ALS Genes: Misregulation and Potential Therapies
Perrone, B., Cognata, V. L., Sprovieri, T., Ungaro, C., Conforti, F. L., Andò, S., & Cavallaro, S. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00717-0 · Cited by 45
Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises
McAlary, L., Chew, Y. L., Lum, J. S., Geraghty, N. J., Yerbury, J. J., & Cashman, N. R. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.581907 · Cited by 48
Opinion: more mouse models and more translation needed for ALS
Fisher, E., Greensmith, L., Malaspina, A., Fratta, P., Hanna, M. G., Schiavo, G., Isaacs, A. M., Orrell, R. W., Cunningham, T. J., & Acevedo‐Arozena, A. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00619-2 · Cited by 45
Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade
Cantara, S., Simoncelli, G., & Ricci, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094809 · Cited by 42
Uses for humanised mouse models in precision medicine for neurodegenerative disease
Nair, R., Corrochano, S., Gasco, S., Tibbit, C., Thompson, D., Maduro, C., Ali, Z., Fratta, P., Acevedo‐Arozena, A., Cunningham, T. J., et al. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09807-2 · Cited by 43
Everett, W., & Bucelli, R. C. (2024) · Neurodegenerative Disease Management · doi:10.1080/17582024.2024.2402216 · Cited by 45
Moazami, M. P., Rembetsy-Brown, J. M., Sarli, S. L., McEachern, H. R., Wang, F., Ohara, M., Wagh, A. A., Kelly, K. L., Krishnamurthy, P. M., Weiss, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.024 · Cited by 40
He, D., Xu, Y. C., Liu, M., & Cui, L. (2023) · Aging and Disease · doi:10.14336/ad.2023.0519 · Cited by 43
Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042320 · Cited by 44
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis
Lovett, A., Chary, S., Babu, S., Bruneteau, G., Glass, J. D., Karlsborg, M., Ladha, S. S., Mayl, K., McDermott, C. J., Bucelli, R. C., et al. (2025) · Muscle & Nerve · doi:10.1002/mus.28372 · Cited by 41
Antisense therapies for movement disorders
Scoles, D. R., & Pulst, S. M. (2019) · Movement Disorders · doi:10.1002/mds.27782 · Cited by 39
Biomarkers for amyotrophic lateral sclerosis
Witzel, S., Mayer, K., & Oeckl, P. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001094 · Cited by 41
Approaches to gene modulation therapy for ALS
Meijboom, K. E., & Brown, R. H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01285-w · Cited by 38
Wang, C., Wang, S., Xue, Y., Zhong, Y., Li, H., Hou, X., Kang, D. D., Liu, Z., Tian, M., Wang, L., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02487-7 · Cited by 45
Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
Jankovic, M., Novakovic, I., Gamil Anwar Dawod, P., Gamil Anwar Dawod, A., Drinic, A., Abdel Motaleb, F. I., Ducic, S., & Nikolic, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189832 · Cited by 36
Meyer, T., Schumann, P., Weydt, P., Petri, S., Weishaupt, J. H., Weyen, U., Koch, J. C., Günther, R., Regensburger, M., Boentert, M., et al. (2024) · Muscle & Nerve · doi:10.1002/mus.28182 · Cited by 37
Ediriweera, G. R., Sivaram, A. J., Cowin, G., Brown, M. L., McAlary, L., Lum, J. S., Fletcher, N. L., Robinson, L., Simpson, J. D., Chen, L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.074 · Cited by 41
Nakamura, A., Ali, S. A., & Kapoor, M. (2020) · Bone · doi:10.1016/j.bone.2020.115461 · Cited by 33
Heckler, I., & Venkataraman, I. (2022) · Journal of Neurophysiology · doi:10.1152/jn.00398.2021 · Cited by 35
Takeuchi, T., Maeta, K., Ding, X., Oe, Y., Takeda, A., Inoue, M., Nagano, S., Fujihara, T., Matsuda, S., Ishigaki, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.006 · Cited by 34
Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice
Cheng, W., Huang, J., Fu, X.-Q., Tian, W.-Y., Zeng, P.-M., Li, Y., & Luo, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.018 · Cited by 32
Therapeutic antisense oligonucleotides for movement disorders
Doxakis, E. (2020) · Medicinal Research Reviews · doi:10.1002/med.21706 · Cited by 33
The expanding application of antisense oligonucleotides to neurodegenerative diseases
Sumner, C. J., & Miller, T. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci186116 · Cited by 32
Self-citationA copper chaperone–mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis
McAlary, L., Shephard, V. K., Wright, G. S. A., & Yerbury, J. J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101612 · Cited by 31
Chen, Y. A., Kankel, M. W., Hana, S., Lau, S. K., Zavodszky, M. I., McKissick, O. P., Mastrangelo, N., Dion, J., Wang, B., Ferretti, D., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00375-w · Cited by 34
Self-citationThe MOE Modification of RNA: Origins and Widescale Impact on the Oligonucleotide Therapeutics Field
Hill, A. C., & Hall, J. (2023) · Helvetica Chimica Acta · doi:10.1002/hlca.202200169 · Cited by 30
Therapeutic targeting of ALS pathways: Refocusing an incomplete picture
Maragakis, N. J., de Carvalho, M. A., & Weiss, M. D. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51887 · Cited by 31
Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease
Cheng, Y., Zhang, S., & Shang, H. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0142 · Cited by 31
Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients
Sabatelli, M., Cerri, F., Zuccarino, R., Patanella, A. K., Bernardo, D., Bisogni, G., Tanel, R., Sansone, V., Filosto, M., Lattante, S., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12437-7 · Cited by 31
Shafie, A., Ashour, A. A., Anwar, S., Anjum, F., & Hassan, M. I. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01499-w · Cited by 29
Amyloid fibril structures and ferroptosis activation induced by ALS-causing SOD1 mutations
Wang, L., Ma, Y., Zhang, M.-Y., Yuan, H., Li, X.-N., Xia, W., Zhao, K., Huang, X., Chen, J., 邹良玉, et al. (2024) · Science Advances · doi:10.1126/sciadv.ado8499 · Cited by 30
Self-citationDNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases
Ge, R., Chen, M., Wu, S., Huang, S., Zhou, P., Cao, M., Zhang, F., Zang, J., Zhu, Y., Li, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60039-2 · Cited by 38
An Overview of Nanomedicines for Neuron Targeting
García-Chica, J., Paraiso, W. K. D., Tanabe, S., Serra, D., Herrero, L., Casals, N., García, J., Ariza, X., Quader, S., & Rodríguez‐Rodríguez, R. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0088 · Cited by 28
Easton, A. E., Jensen, M. L., Wang, C., Hagedorn, P., Li, Y.-W., Weed, M. R., Meredith, J. E., Guss, V. L., Jones, K. M., Gill, M. B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.027 · Cited by 27
Metadata
- Authors
- McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., Schoch, K. M., Hoye, M. L., Shabsovich, M., Sun, L., Luo, Y., Zhang, M., Thankamony, S., Salzman, D. W., Cudkowicz, M., Graham, D. L., Bennett, C. F., Kordasiewicz, H. B., Swayze, E. E., & Miller, T. M.
- Affiliations
- Biogen (United States) (US)
- Ionis Pharmaceuticals (United States) (US)
- Washington University in St. Louis (US)
- Harvard University (US)
- Corresponding author
- Miller, Timothy M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-16
- Volume
- 128
- Issue
- 8
- Pages
- 3558-3567
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6063493
- OpenAlex
- W2884390718
- Cited by
- 279
- References
- 46
- Citations by year
- 2026: 30 · 2025: 36 · 2024: 48 · 2023: 35 · 2022: 32 · 2021: 30 · 2020: 42 · 2019: 22 · 2018: 4
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Biogen
- Ionis Pharmaceuticals
- National Institutes of Health (50 and)
- National Institute of Neurological Disorders and Stroke (U01NS084970, R01NS078398)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- antisense oligonucleotides, amyotrophic lateral sclerosis, SOD1, SOD1 G93A mice, familial ALS, compound muscle action potential, neurofilament heavy chain, biomarkers, survival extension, ALS therapeutics
- MeSH terms
- Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Disease Models, Animal, Humans, Superoxide Dismutase, Muscle, Skeletal, Oligodeoxyribonucleotides, Antisense, Rats, Rats, Transgenic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
